Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Brenner Tumor 1

Interventions

Paclitaxel 15Carboplatin 15Taxes 9Cisplatin 8Topotecan 4Docetaxel 4Filgrastim 3pegfilgrastim 2paclitaxel poliglumex 2liposomal doxorubicin 2Methods 2Gemcitabine 2GEN-1 2Etoposide 2Erlotinib Hydrochloride 2Educational Status 2Early Intervention, Educational 2Chemotherapy, Adjuvant 2vandetanib 1rilotumumab 1oregovomab 1motesanib diphosphate 1elesclomol 1dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Watchful Waiting 1VTX-2337 1Trabectedin 1Surgical Procedures, Operative 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Fallopian Tube Neoplasms × elesclomol × Clear all
NCT00888615 2021-10-20

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

GOG Foundation

Phase 2 Completed
58 enrolled 13 charts
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡